The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Cost-effectiveness of continuous BTK inhibitors in patients with CLL: a Medicare financial analysis
Joanna Rhodes, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, shares insights into the cost-effectiveness of continuous BTK inhibitor therapy in patients with chronic lymphocytic leukemia (CLL). She notes that acalabrutinib offers a favorable cost profile compared to ibrutinib and zanubrutinib, with lower costs associated with adverse events. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
